Skip to Main Content


Current Issue
Volume 3,
Issue 20,
October 22, 2019

Featured Content

DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes

DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes

Myeloablative vs reduced intensity T-cell–replete haploidentical transplantation for hematologic malignancy

Haploidentical transplantation has emerged as a viable alternative to other donor sources and has made allogeneic transplantation available to many more patients throughout the world. A number of groups have explored both T-cell–depleted and T-cell–replete strategies. In this study from the Center for International Blood and Marrow Transplant Research, Solomon et al made important findings on the impact of conditioning regimen intensity in patients receiving T-cell replete transplants.

Butyrogenic bacteria after acute graft-versus-host disease (GVHD) are associated with the development of steroid-refractory GVHD

The role of the microbiome in the development and severity of a number of immunological disorders is emerging. In a Stimulus Report, Golob and colleagues explore the impact of butyrogenic bacteria on the course of graft-versus-host disease, with interesting and clinically relevant findings that could lead to future interventions.

T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma

Chimeric antigen receptor (CAR) T-cell–based therapy has shown success in the treatment of patients with advanced refractory multiple myeloma. However, concerns include the multiple lines of therapy that these patients have experienced and how these treatments impact the ability to produce high-quality CAR T cells. The Stimulus Report by Garfall and colleagues explores this topic, highlighting the impact that prior treatments may have on CAR T-cell production.

Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance

The treatment of limited stage I/II follicular non-Hodgkin lymphoma is an area of considerable debate. Tobin et al evaluated the outcomes of these patients in a large cohort of 365 patients in a study organized by the Australian Lymphoma Alliance. It may help guide therapy and future studies.

High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells

Mixed-lineage leukemia (MLL) chromosomal translocations have been identified as a common finding in some patients with acute myeloid leukemia. To explore the biology of leukemias with the t(9;11) chromosomal translocation involving MLL, Jeong and colleagues used CRISPR/Cas9 technology to transform human umbilical cord blood stem cells, which rapidly induced leukemia upon adoptive transfer to immunodeficient animals. This approach has resulted in a novel model to study the biology of these leukemias.

Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal